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using the UKPDS risk engine. Statin adherence was measured as pill days cov-
ered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was 
measured in costs per quality-adjusted life-year (QALY) form the health care-
payers’ perspective. Results: For an average patient aged 60 at diagnosis, statin 
treatment was highly cost-effective at around € 2,300 per QALY. Favourable cost-
effectiveness was robust in sensitivity analysis. Differences in age and 10-year 
cardiovascular risk showed large differences in cost-effectiveness from more 
than € 100,000 per QALY to almost being cost saving. For the average patient aged 
40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effec-
tive. ConClusions: Despite the non-adherence levels observed in actual practice, 
statin treatment is cost-effective for primary prevention in patients newly diagnosed 
with type 2 diabetes. Due to large differences in cost-effectiveness according to differ-
ent risk and age groups, the efficiency of the treatment could be increased by targeting 
patients with relatively higher cardiovascular risk and higher ages.
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DeVeloPment of noVel ImagIng tests to seleCt PatIents for 
InDIVIDualIzeD theraPIes: are they Worth further InVestment?
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Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: Patients with a recent transient ischemic attack (TIA) or minor ischemic 
stroke who receive medicines have a 10-year risk of about 16% for any recurrent 
stroke. Non-invasive molecular imaging technologies are currently being developed 
to improve individual stroke risk prediction. We estimated the potential lifetime cost-
effectiveness of a novel imaging test for stroke prediction in an early stage of develop-
ment. Methods: Decision modelling was used to estimate the potential value of an 
add-on test that could identify which patients with a recent TIA or minor ischemic 
stroke should undergo surgery instead of receive medicines. The comparator was 
patient management according to Dutch guidelines. Test sensitivity and specificity 
were varied from 0-100% and its cost was set at € 350. Different age- and gender-spe-
cific subgroups were examined to see how much cost-effectiveness varied. Results: 
A perfect add-on test (100% sensitivity and specificity) for 60-year-old men appears to 
be cost-effective versus Dutch guidelines, with an estimated 0.61 QALY gain, € 3,986 
cost increase, and an incremental cost-effectiveness ratio (ICER) of € 6,534/QALY 
gained. A test with sensitivity= 60% and specificity= 100% increases both health (0.14 
QALYs) and costs (€ 2,888), resulting in an ICER of € 20,338/QALY gained. Similarly, a 
test with sensitivity= 100% and specificity= 60% increases both health (0.29 QALYs) 
and costs (€ 5,784), resulting in an ICER of € 19,946/QALY gained. ConClusions: An 
imaging test that improves risk prediction and therefore treatment decisions for 
patients with a recent TIA or minor ischemic stroke has the potential to optimize cost-
effectiveness by reducing the risk of recurrent stroke. However, reduced sensitivity 
or specificity of the test reduces its cost-effectiveness versus the Dutch guidelines. 
Developers must consider if the minimum level of accuracy required to be cost-effec-
tive is close to the maximum capability of the test. Model-based analyses are valu-
able in facilitating decisions about investments in the further development of a test.
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objeCtives: At the population level, disease management programs (DMPs) for heart 
failure (HF) have proven to be effective in increasing quality-adjusted survival and 
reducing the rate of hospital readmission. However, a systematic assessment as to 
whether these outcomes could still be improved upon by tailoring the content and 
structure of such DMPs to the risk profile of the individual patient has not yet been 
conducted. Using data from a previously conducted randomized controlled trial, the 
purpose of this study was to explore the clinical and health economic consequences 
of assigning different DMPs to different risk categories of HF patient. Methods: The 
analysis was conducted alongside the COACH study, in which 1023 patients were ran-
domly assigned to one of three DMPs: care-as-usual (routine follow-up by a cardiolo-
gist), basic additional support by a nurse specialized in HF management (HF-nurse), 
and intensive additional support by an HF-nurse. The Subpopulation Treatment Effect 
Pattern Plot (STEPP) methodology was applied to graphically establish suitable cut-
offs for stratifying patients into different risk categories based on their predicted 
18-month mortality risk. Separate cost-effectiveness analyses were subsequently 
performed within each of these strata to determine per risk category the DMP that 
would be optimal in terms of survival time and costs. Results: Based on the STEPP 
analysis, a cut-off of 0.17 was selected to classify 346 (33.8%) patients as low risk and 
677 (66.2%) patients as high risk. At a threshold value of € 10,000 per life-year, this 
resulted in an 82.9% probability that intensive support would be optimal for low-risk 
patients and an 83.6% probability that basic support would be optimal for high-risk 
patients. ConClusions: Assigning different DMPs to different risk groups of patient 
improved outcomes and reduced costs. Tailoring the content and structure of such 
programs to the risk profile of the individual patient seems therefore desired.
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objeCtives: Dabigatran was recommended by the Pharmaceutical Benefits 
Advisory Committee (PBAC) in March 2011 for the treatment of non-valvular atrial 
fibrillation (NVAF) but was not listed on the Pharmaceutical Benefits Scheme (PBS) 
for over two years. This analysis examines the cost-effectiveness of dabigatran 
and the opportunity cost of delayed reimbursement from a societal perspec-
tive. Methods: This analysis estimated the costs for dabigatran compared with 
warfarin and a mixed comparator (warfarin/aspirin/untreated) reflective of current 
ICER of € 11,000/QALY which is below the threshold deemed acceptable from Italian 
payers (25.000€ -40.000€ ). In the subgroups analyses, rivaroxaban demonstrated to 
be a dominant strategy (more effective and less costly). Sensitivity analyses showed 
the robustness of the results. ConClusions: Rivaroxaban is a cost-effective alter-
native to VKA and is cost-saving for the SSN in the treatment of NVAF patients at 
highest unmet medical need.
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objeCtives: To estimate the cost-effectiveness of dabigatran etexilate (dabigatran) 
for the secondary prevention of deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) from the perspective of the UK National Health Service. Methods: A 
Markov model was developed to estimate costs and outcomes over the lifetime of 
a cohort of patients receiving either dabigatran (150mg given orally, twice daily) 
or placebo for 6 months after having completed 6 to 18 months of anticoagulation 
treatment for a DVT or PE. Modelled events included recurrent DVT and PE, major 
bleeding (including long-term disability from intracranial haemorrhage), clinically 
relevant non-major bleeding, myocardial infarction, unstable angina, pulmonary 
hypertension, severe postthrombotic syndrome, and death. Efficacy and safety 
parameters were based on the RE-SONATE study; the period of follow-up was 6 
months with an extension to 18 months. Probabilities of recurrent DVT and PE after 
trial follow-up were based on a prospective cohort study of 1,626 patients followed-
up for a median of 50 months and were assumed to be equivalent in both treatment 
groups. Utility estimates were based on EQ-5D data collected in dabigatran trials and 
published literature. The mean duration of therapy was based on the RE-SONATE 
study; other costs were based on NHS Reference Costs and published literature. 
Costs and outcomes were discounted at 3.5% per annum. Univariate and probabilis-
tic sensitivity analyses were performed. Results: In the base-case analysis, mean 
total costs for dabigatran and placebo patients were £7,147 and £7,520 respectively; 
mean QALYs were 13.089 and 13.070 respectively. Dabigatran was dominant; the 
probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per 
QALY was 63%. In univariate sensitivity analysis, dabigatran was dominant in all 
analyses. ConClusions: This analysis suggests that dabigatran is likely to be cost-
saving compared to placebo for the secondary prevention of DVT and PE in the UK.
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objeCtives: Statins are the standard treatment for cardiovascular disease (CVD) 
prevention however, with limited effect on triglyceride (TG) and high-density lipo-
protein-cholesterol (HDL-C) in mixed hyperlipidemia. Fenofibric acid (FA) is approved 
for co-administration with statins to reduce TG and increase HDL-C in patients with 
mixed hyperlipidemia at goal for LDL-C with statins. This study assesses the cost-
effectiveness of FA combined with low (LDS) or medium (MDS) dose statins versus 
low, medium or high (HDS) dose statins alone in the prevention of CVD in Taiwanese 
patients with type 2 diabetes and mixed hyperlipidemia. Methods: A 5-health-
state Markov model for diabetic patients with mixed hyperlipidemia already 
treated with statin (TG:250mg/dl; HDL-C:35mg/dl; LDL-C:115mg/dl; TC:200mg/dl) 
was developed, using a lifetime horizon with annual cycles. PROCAM (first event) 
and Framingham (subsequent event) risk equations were used. Effects on TG, HDL-C 
and TC for each comparator were derived from pooled simvastatin, atrovastatin 
and rosuvastatin trials. Drug and event costs were based on official national data-
bases. Annual discounting (5%) was applied to outcomes and costs. Incremental cost 
(€ ) per Quality of Life Gained (QALYG) was calculated from the Taiwanese Bureau 
of National Health Insurance perspective. Results: Compared to LDS and MDS, 
treatment with FA+LDS resulted in higher costs (€ 2,225; € 1,676) but more QALYG 
(0.311; 0.064), resulting in an incremental cost-effectiveness ratio of € 7,161/QALYG 
and € 26,375/QALYG respectively. Compared to HDS, FA+LDS costs were lower with 
slightly less QALYG (ICER: € 183,490/QALYG). Compared to FA+MDS, FA+LDS was 
dominant with lower costs (-€ 900) and higher QALYG (0.004). Sensitivity analyses 
showed robustness of the results. The probability for FA+LDS being cost-effective 
(< GDP threshold € 45,400) is 100% for both, LDS and MDS. ConClusions: In this 
specific mixed hyperlipidemia population, FA+LDS is likely to be a cost-effective 
alternative to LDS or MDS alone, potentially allowing for lower statin doses in pre-
venting CVD.
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objeCtives: Statins reduce the risk of cardiovascular events in patients 
with diabetes. The aim of this study is to determine whether statin treatment 
for primary prevention in newly diagnosed type 2 diabetes is cost-effective, 
taking non-adherence, baseline risk, and age into account. Methods: A cost-
effectiveness analysis was performed using a Markov model with a time horizon 
of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch 
population of primary prevention patients with newly diagnosed diabetes from 
the Groningen Initiative to Analyse Type 2 Diabetes Treatment database (GIANTT), 
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patients with a recent ischemic stroke/TIA. The purpose of this study was to esti-
mate the cost-effectiveness of two screening methods for detection of silent AF, 
brief intermittent long-term ECG recordings at regular time intervals and short-
term 24-hours continuous ECG (Holter-ECG) and to compare them to a no screening 
alternative in patients with a recent ischemic stroke. Methods: The long-term 
(20 year) costs and effects of brief intermittent long-term ECG recordings at regular 
time intervals and short term continuous ECG are estimated with a decision ana-
lytic model combining the result of a clinical study and epidemiological data. The 
structure of a cost-effectiveness analysis was used in this study. The short term 
decision tree model analyzed the screening procedure until the onset of antico-
agulant treatment. The second part of the decision model follows a Markov design 
simulating the patients for 20 years. Results: Continuous 24 h ECG recording was 
dominated by intermittent ECG due to lower sensitivity and higher costs. The base 
case analysis compared intermittent-ECG screening with no screening of patients 
with recent stroke. The implementation of the screening program on 1000 patients 
resulted in 10,9 avoided strokes and the gain of 29,2 life years or 22,7 QALYs and 
cost savings of € 55 000. ConClusions: Screening of silent AF by intermittent ECG 
recordings in patients with a recent ischaemic stroke is cost-effective use of health 
care resources saving costs, lives and quality of life.
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Issues WIth Cost-effeCtIVeness moDellIng of DIagnostIC tests – Case 
stuDy of IsChaemIC CarDIomyoPathy
Thokala P., Thomas S., Campbell F.
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objeCtives: To estimate the cost-effectiveness of diagnostic pathways for assessing 
patients with ischaemic cardiomyopathy to identify patients with viable myocar-
dium with a view to revascularisation. Methods: A decision analytic model was 
developed to estimate the cost-effectiveness of diagnostic strategies for assessing 
patients with ischaemic cardiomyopathy. The different diagnostic pathways were 
applied to a hypothetical cohort of patients with ischaemic cardiomyopathy and the 
probability of successful identification of viable myocardium and non-viable myo-
cardium was determined by the accuracy of the diagnostic pathway. It was assumed 
that patients diagnosed with viable myocardium would be managed promptly by 
revascularisation and that the patients diagnosed with non-viable myocardium 
would be on medical therapy. The model assigned each patient a risk of death and 
rehospitalisation depending upon whether they are truly viable and whether they 
had revascularisation or not. Each patient then accrued lifetime QALYs. Health care 
costs were also accrued through measuring diagnostic costs and treatment costs, 
depending on the pathway and their treatment status. Results: All the diagnostic 
pathways are cost-effective when compared with no testing at current NICE thresh-
old, this suggests that all the current services for diagnosing viable myocardium 
are a cost effective use of NHS resources irrespective of the diagnostic pathway 
used. For services that need to decide the most cost-effective strategy starting from 
scratch, then Stress CMR is the most cost-effective strategy. ConClusions: There 
are a number of issues with abstracting the data for cost-effectiveness modelling 
of diagnostic tests. For example, the diagnostic accuracy depends upon the type of 
index test, gold standard test and threshold used. Furthermore, the benefits of treat-
ments after diagnosis are not always clear and might be linked to the type of diag-
nostic test. Appropriate caution needs to be taken when evaluating diagnostic tests.
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objeCtives: Ivabradine is approved by the European Medicine Agency for the treat-
ment of Chronic Heart Failure (CHF) NYHA II to IV class with systolic dysfunction 
in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with 
standard therapy including beta-blocker therapy or when beta-blocker therapy is 
contraindicated or not tolerated. The study objective was to perform a cost-effective-
ness analysis of ivabradine based on the outcomes of the SHIFT clinical trial from 
the perspective of the Irish Health Service Executive (HSE). Methods: A six health 
state Markov model with health states for CHF NYHA classes I to IV, alive, and dead 
was adapted to the Irish health care setting. The economic evaluation compared 
the cost-effectiveness of ivabradine in combination with standard therapy versus 
standard therapy alone. A lifetime horizon was chosen in the base case analysis. 
Costs and effects were discounted at 4% per year. Deterministic and probabilistic 
sensitivity analyses were performed. Health state utilities were estimated from 
EQ-5D index scores obtained from the SHIFT clinical trial. The base case analysis 
was based on heart failure outcomes and associated costs. Results: When used 
in addition to standard therapy, ivabradine increased discounted health care costs 
by € 2169 for a 0.23 QALY gain, resulting in an incremental cost per QALY gained of 
€ 9,426. In no case of the deterministic sensitivity analysis did the cost per QALY 
gained increase above € 20,000. The probability of the cost-effectiveness of ivabradine 
at a willingness to pay threshold of € 45,000 per QALY gained was estimated to be 
approx. 100%. ConClusions: When used in addition to standard therapy, based 
on heart failure outcomes and associated costs, ivabradine had an incremental cost 
per QALY gained of € 9,426 with an approximately 100% probability of being cost-
effective at a willingness to pay threshold of € 45,000 per QALY gained.
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objeCtives: Hypertension affects 41% of male and 31% of female adults in Belgium; 
13% of these are believed to be refractory to standard hypertension treatment (uncon-
practice. A societal perspective incorporated the following indirect costs: formal and 
informal long term care costs for stroke, productivity losses associated with stroke 
and carers, and productivity, out of pocket and travel costs associated with INR 
testing in both metropolitan and rural settings. The opportunity cost of a delayed 
dabigatran PBS listing was estimated over a 2 year period. Estimates were derived 
using the economic model presented to the PBAC. Results: When incorporating a 
societal perspective, dabigatran was cost saving versus both warfarin and the mixed 
comparator. Dabigatran is estimated to save an average of $2,011 and $3,994 per 
patient per year for patients in metropolitan and rural settings respectively com-
pared with current practice. In the more than two years since the initial PBAC rec-
ommendation of dabigatran it is estimated over 150,000 patients have been denied 
affordable access to treatment, resulting in $47.9 million in costs to Medicare, $5.2 
million in patient out of pocket costs and 470,000 hours of lost productivity due to 
avoidable INR testing. Importantly, 4,059 strokes and 902 resultant deaths could have 
been avoided in this time compared to current practice. ConClusions: Dabigatran 
is a cost-effective treatment for stroke prevention in patients with NVAF in Australia 
and is cost saving compared to current therapy (warfarin, aspirin and no treatment) 
when a societal perspective is taken.
PCV87
ComPrehensIVe oVerVIeW: effICaCy, tolerabIlIty anD Cost- 
effeCtIVeness of Irbesartan
Gialama F.1, Maniadakis N.2
1National School of Public Health, ATHENS, Greece, 2National School of Public Health, Athens, 
Greece
objeCtives: Hypertension represents a major health problem, affecting more than 1 
billion adults worldwide. Irbesartan, an angiotensin II receptor blocker, is considered 
to be a highly effective treatment in the management of hypertension. Therefore 
this study aims to evaluate the efficacy, safety and tolerability profile, as well as 
the cost-effectiveness of irbesartan in the treatment of hypertension. Methods: 
A review of the literature was conducted using the electronic databases Medline, 
Cochrane and HEED of search terms relating to irbesartan efficacy, tolerability and 
cost-effectiveness and the results were synthesized. Results: Findings from the 
present analysis show that irbesartan either as monotherapy or in combination 
with other agents can have significant reductions in Blood Pressure, both systolic 
and diastolic, when compared to other alternative treatment options. Irbesartan 
was also found to have a renoprotective effect, independent of its blood pressure 
lowering effect in patients with type 2 diabetes and nephropathy. Irbesartan also 
delayed onset of end-stage renal disease (ESRD) and reduced the cumulative inci-
dence of ESRD. Furthermore, Irbesartan demonstrated an excellent safety and toler-
ability profile. Overall adverse event incidence with irbesartan was comparable with 
other antihypertensive drugs. Most common adverse events were headache, fatigue 
and dizziness. In terms of economic analyses, compared to other antihypertensive 
therapy alternatives, irbesartan increased life expectancy and lead to substantial 
cost savings. ConClusions: Evidence indicates that treating patients with hyper-
tension alone or with type II diabetes and nephropathy, can control hypertension, 
prolong life and reduce costs, in relation to other existing alternatives.
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Post thrombotic syndrome (PTS) is a chronic condition that develops in up to 50% of 
patients after deep vein thrombosis and is characterized by debilitating complaints 
of the leg. Two randomized controlled trials (RCT) showed that elastic compression 
stocking (ECS) therapy for 2 years after DVT reduces the PTS incidence by approxi-
mately 50%. A recent management study showed that tailored duration of ECS ther-
apy on individual patient characteristics may result in a reduction of ECS therapy of 
18 months for 50% of patients with an even lower incidence of PTS. However, these 
results may be biased. objeCtives: To explore the cost-effectiveness of individually 
tailored ECS therapy (IND) compared with a standard duration of 2 years ECS therapy 
(STANDARD), from a health care perspective in order to inform the design of an RCT 
comparing the two treatment options. Methods: A decision-analytic probabilistic 
Markov model with lifelong time horizon was used. Health states in the model are: 
No PTS with stocking, No PTS without stocking, Mild to moderate PTS, Severe PTS, 
and Death. Transition probabilities, costs, and utilities were obtained from litera-
ture. The incidence of PTS was taken from the trials (STANDARD: 2-year incidence 
24.5%) and the management study (IND: 2-year incidence 21.1%). The delta for non-
inferiority of a future RCT was determined, and uncertainty was assessed in value 
of information analyses. Results: Based on current evidence IND saves € 2,292 and 
gains 0.14 quality adjusted life years (QALY) per patient compared to STANDARD. 
This result is however highly uncertain, and future research is valuable. The savings 
of IND amount to € 306 when assuming equal incidence of PTS. If PTS incidence is 
7% higher in IND, the treatment seizes to be cost-effective. ConClusions: Based 
on current limited evidence, IND may dominate STANDARD. Future research is 
worthwhile, and may be informed by this modeling study.
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objeCtives: Prolonged brief intermittent arrhythmia screening has been suggested 
to substantially improve detection of silent paroxysmal atrial fibrillation (AF) in 
